IIIC

Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference

Retrieved on: 
Thursday, May 2, 2024
Infection, Clostridioides difficile infection, Congress, University, University of Houston, Vancomycin, Professor, Poster, Recurrence, IIIC, Disease, DNA, Patient, Treatment, Microbiology, Doctor of Pharmacy, Diarrhea, CDI, Fidaxomicin, Clostridioides difficile, Houston Community College, Pharmaceutical industry

The presentation included additional analyses of clinical and microbiological data from the Phase 2b Segment of the trial.

Key Points: 
  • The presentation included additional analyses of clinical and microbiological data from the Phase 2b Segment of the trial.
  • Commenting on his presentation, Dr. Garey stated: "This randomized, active-controlled study showed ibezapolstat was comparable to vancomycin in achieving clinical cure in patients with mild-to-moderate CDI.
  • The presentation and poster are available on the Acurx Pharmaceuticals website following their respective presentations at the conference.
  • www.acurxpharma.com
    The complete Phase 2 results are being prepared for submission to a prominent scientific journal.

Acurx Announces Ibezapolstat Scientific Poster and Update on its Pol IIIC Pipeline Presented at ECCMID 2023 Scientific Conference

Retrieved on: 
Wednesday, April 19, 2023
ISLAND, VRE, Clostridioides difficile infection, DNA, DNA-binding protein, University, IV, Flagellum, Public, IIIC, MRSA, Infection, Genetically modified bacteria, Houston Community College, Solubility, DRSP, Movement, Congress, Professor, ECCMID, Vancomycin, European, Metronidazole, University of Houston, Fidaxomicin, Susceptibility, Poster, Principal, Pharmacology, Recurrence, Virulence, Safety, Microbiology, Vaccine, Pharmacy

C. difficile strains with reduced susceptibility to metronidazole, vancomycin, or fidaxomicin were susceptible to ibezapolstat, confirming its unique mechanism of action.

Key Points: 
  • C. difficile strains with reduced susceptibility to metronidazole, vancomycin, or fidaxomicin were susceptible to ibezapolstat, confirming its unique mechanism of action.
  • To study anti-virulence effect, our group investigated an under-studied virulence property of C difficile, namely, flagellar movement of the organism.
  • All of these positive and unexpected findings reflect the unique mode of action in inhibiting DNA pol IIIC and support the continued development of ibezapolstat to treat C. difficile infection."
  • The poster and presentation are available on the Company's website www.acurxpharma.com.

Acurx Pharmaceuticals, Inc. to Discuss 2022 Third Quarter Financial Results on November 14, 2022 Conference Call and Provide Business Update

Retrieved on: 
Tuesday, November 1, 2022
Security (finance), Marketing, MRSA, Clostridioides, DNA, Infection, IIIC, Clostridioides difficile (bacteria), Securities and Exchange Commission (Philippines), Annual report, Methicillin-resistant Staphylococcus aureus, Gram, VRE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Gram-positive bacteria, CDI, Maintenance, GAIN, Private Securities Litigation Reform Act, Company, Clostridioides difficile infection, FDA, Enterococcus, Patient, Food, Fast Track, QIDP, CDC, Act, Firmicutes, GPSS, DRSP, Pharmaceutical industry, Actinobacteria

It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections.

Key Points: 
  • It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections.
  • The Company successfully completed Phase 1 and Phase 2a clinical trials of ibezapolstat.
  • The CDC has designated C. difficile as an urgent threat highlighting the need for new antibiotics to treat CDI.
  • Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections.

Acurx Pharmaceuticals, Inc. to Discuss 2022 Second Quarter Financial Results on August 16, 2022 Conference Call and Provide Business Update

Retrieved on: 
Thursday, August 4, 2022
Fast Track, Private Securities Litigation Reform Act, Annual report, Security (finance), Marketing, GPSS, Gram, Clostridioides difficile (bacteria), CDI, IIIC, Patient, Food, MRSA, Company, Clostridioides, Infection, QIDP, Enterococcus, Securities and Exchange Commission (Philippines), FDA, Maintenance, Act, VRE, DRSP, GAIN, Firmicutes, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Clostridioides difficile infection, DNA, Methicillin-resistant Staphylococcus aureus, Gram-positive bacteria, CDC, Pharmaceutical industry, Actinobacteria

It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections.

Key Points: 
  • It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections.
  • The Company successfully completed Phase 1 and Phase 2a clinical trials of ibezapolstat.
  • Acurx is currently enrolling patients in its Phase 2b vancomycin-controlled efficacy study in a 1:1 randomized trial of a total of 64 patients with CDI.
  • Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections.

European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent Patients (≥12 Years of Age) With Stage IIB or IIC Melanoma Following Complete Resection

Retrieved on: 
Friday, June 24, 2022
FDA, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, MSD, Patient, Research, IIIC, Peripheral tolerance, EC, Fourth grade, Marketing, Growth, Cancer, Pneumonitis, Skin cancer, Royal commission, Princess, Incidence, PD-L2, Recurrence, Melanoma, IIC, Pembrolizumab, MRK, Population, Ageing, CHL, NYSE, Diarrhea, RFS, III, Death, Infection, European Commission, Survival, Adult, Creatinine, Merck & Co., Ligand, Adolescence, Biomarker, IIB, Prednisone, Disease, PD-1, PD-1 and PD-L1 inhibitors, Prognosis, PD-L1, Risk, Selection, Toxicity, TNBC, Safety, Vaccine, Pharmaceutical industry, Medical imaging, Medical device, Merck, EU, Cytomegalovirus

Additionally, the EC approved expanding the indications for KEYTRUDA in advanced (unresectable or metastatic) melanoma and stage III melanoma (as adjuvant treatment following complete resection) to include adolescent patients aged 12 years and older.

Key Points: 
  • Additionally, the EC approved expanding the indications for KEYTRUDA in advanced (unresectable or metastatic) melanoma and stage III melanoma (as adjuvant treatment following complete resection) to include adolescent patients aged 12 years and older.
  • In the EU, KEYTRUDA was previously approved for the treatment of adult patients with advanced (unresectable or metastatic) melanoma and for the adjuvant treatment of adult patients with stage III melanoma and lymph node involvement who have undergone complete resection.
  • Selected KEYTRUDA (pembrolizumab) Indications in the U.S.
    KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma.
  • KEYTRUDA is indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB, IIC, or III melanoma following complete resection.

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection

Retrieved on: 
Friday, May 20, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Royal commission, Cancer, MRK, PD-1 and PD-L1 inhibitors, IIB, Risk, Creatinine, Death, Disease, Ageing, Annual general meeting, PD-L2, Survival, Fourth grade, Ligand, Incidence, Adolescence, Abstract, Infection, European Commission, Patient, IIIC, PD-1, Pneumonitis, Skin cancer, Society, TNBC, American Society of Clinical Oncology, Adult, Peripheral tolerance, CHL, Research, PD-L1, Pembrolizumab, Recurrence, CHMP, European Medicines Agency, Prednisone, III, Selection, Union, ASCO, Biomarker, Growth, European Directive on Traditional Herbal Medicinal Products, Diarrhea, IIC, NYSE, Merck & Co., Melanoma, Vaccine, Pharmaceutical industry, Medical imaging, Medical device, Cytomegalovirus, Merck

Additionally, the CHMP recommended expanding the indications for KEYTRUDA in advanced (unresectable or metastatic) melanoma and stage III melanoma (as adjuvant treatment following complete resection) to include adolescent patients aged 12 years and older.

Key Points: 
  • Additionally, the CHMP recommended expanding the indications for KEYTRUDA in advanced (unresectable or metastatic) melanoma and stage III melanoma (as adjuvant treatment following complete resection) to include adolescent patients aged 12 years and older.
  • 0.00658) in patients 12 years and older with stage IIB and IIC melanoma following complete resection.
  • KEYTRUDA is indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB, IIC, or III melanoma following complete resection.
  • Pneumonitis occurred in 8% (31/389) of adult patients with cHL receiving KEYTRUDA as a single agent, including Grades 3-4 in 2.3% of patients.

Acurx Pharmaceuticals, Inc. to Discuss 2022 First Quarter Financial Results on May 11, 2022 Conference Call and Provide Business Update

Retrieved on: 
Friday, April 29, 2022
MRSA, QIDP, DNA, Securities and Exchange Commission (Philippines), Infection, Clostridioides, DRSP, Patient, Annual report, FDA, Clostridioides difficile (bacteria), GAIN, Enterococcus, Food, Gram-positive bacteria, Clostridioides difficile infection, Company, Act, Gram, Private Securities Litigation Reform Act, CDI, Security (finance), Marketing, CDC, VRE, Firmicutes, Methicillin-resistant Staphylococcus aureus, Fast Track, GPSS, IIIC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Maintenance, Pharmaceutical industry, Actinobacteria

It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections.

Key Points: 
  • It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections.
  • The Company successfully completed Phase 1 and Phase 2a clinical trials of ibezapolstat.
  • Acurx is currently enrolling patients in its Phase 2b vancomycin-controlled efficacy study in a 1:1 randomized trial of a total of 64 patients with CDI.
  • Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections.

Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca

Retrieved on: 
Friday, April 29, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Cancer, NK, Antibody, Novo Nordisk, Safety, Immune system, Euronext Paris, Progression-free survival, PD-L1, PFS, Patient, Oncology, Journal, European Society for Medical Oncology, Lymphatic system, Neoplasm, NSCLC, Lung cancer, ESMO, IPH, ORR, American Journal of Clinical Oncology, Bristol Myers Squibb, Oleclumab, AstraZeneca, IPHA, CRT, Squamous cell carcinoma, Tumor microenvironment, Congress, IIIC, Survival, Sanofi, Pharmaceutical industry, Vaccine, Monalizumab, Durvalumab, Nasdaq, MD, Intrinsic and extrinsic properties

Dosing of the first patient in this trial has triggered a $50 million milestone payment from AstraZeneca to Innate.

Key Points: 
  • Dosing of the first patient in this trial has triggered a $50 million milestone payment from AstraZeneca to Innate.
  • We are very pleased that our key late-stage asset, monalizumab, has progressed into a second Phase 3 trial with our partner, AstraZeneca.
  • Detailed results from the randomized COAST Phase 2 trial were published in the Journal of Clinical Oncology on April 22, 2022.
  • Including the $50 million payment triggered by dosing the first patient in the Phase 3 PACIFIC-9 clinical trial, Innate Pharma has received $450 million to date.

Acurx Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28-30, 2022 from 9:00 a.m. - 5:00 p.m. EDT

Retrieved on: 
Wednesday, March 16, 2022
Recurrence, IIIC, MRSA, Patient, Biotechnology, VRE, Private Securities Litigation Reform Act, Chief executive officer, Infection, Plasma, Conference, FDA, Fireside, Infectious Diseases Society of America, Firmicutes, Methicillin-resistant Staphylococcus aureus, Clostridioides difficile infection, Q&A, Primary energy, Health information technology, NASDAQ, EDT, Kepler-86, Tobacco Products Scientific Advisory Committee, Clostridioides, Gram-positive bacteria, Financial services, Company, Got Game Entertainment, DRSP, CEO, Charles M. Vest, Clostridioides difficile (bacteria), QIDP, CDI, DNA, Fireside chats, Gram, Enterococcus, Marketing, Pharmaceutical industry, Health care, Actinobacteria

Mr. Luci will be presenting during the Fireside Chat with Acurx Pharmaceuticals, Inc. at 9:30 am ET on Monday, March 28, 2022.

Key Points: 
  • Mr. Luci will be presenting during the Fireside Chat with Acurx Pharmaceuticals, Inc. at 9:30 am ET on Monday, March 28, 2022.
  • The conference will feature company presentations, fireside chats, roundtable discussions, and live Q&A with CEOs moderated by Maxim Research Analysts.
  • About Acurx Pharmaceuticals, Inc. Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections.
  • However, while we may elect to update these forward- looking statements at some point in the future, we specifically disclaim any obligation to do so.

Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update

Retrieved on: 
Monday, March 7, 2022
Capsule, Exotoxin, CDI, Clostridioides difficile (bacteria), DRSP, The New England Journal of Medicine, Inflammation, Clostridioides, Extrapyramidal system, Firmicutes, Kepler-86, Private Securities Litigation Reform Act, Enterococcus, Vancomycin, Wall, Germination, Metabolism, Company, Incidence, IDSA, Risk, Pharmacokinetics, Infection, IIIC, QIDP, Virulence, Marketing, Maintenance, Gram-positive bacteria, Epithelium, Methicillin-resistant Staphylococcus aureus, Liver, VRE, NASDAQ, Clinical, Gram, Recurrence, Patient, GUH, Hospital, Death, Actinobacteria, Microorganism, GI, DNA, Safety, Lessa, Structural Classification of Proteins database, Diarrhea, Mortality, MRSA, Pharmaceutical industry, Dietary supplement

David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:

Key Points: 
  • David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:
    About the Ibezapolstat Phase 2 Clinical Trial.
  • In this cohort, 10 patients with diarrhea caused by C. difficile were treated with ibezapolstat 450 mg orally, twice daily for 10 days.
  • About Acurx Pharmaceuticals, Inc. Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections.
  • However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so.